RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

Stock News05-11

RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE). This study is part of the company's broader program of planned Phase 2b trials targeting various thromboembolic cardiovascular indications. VTE remains a leading cause of morbidity and mortality in patients with cardiovascular disease, affecting approximately 10 million people globally each year. A significant proportion of these patients are inadequately treated or discontinue therapy due to the bleeding risks associated with current anticoagulant medications. Vortosiran is a small interfering RNA (siRNA) therapeutic designed for thromboembolic diseases. It works by precisely and durably inhibiting coagulation factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and suppressing FXI activity. This mechanism aims to provide robust protection against thromboembolism while significantly reducing the risk of bleeding. Compared to existing anticoagulant therapies, vortosiran has the potential to enhance clinical benefits for patients alongside a lower bleeding risk. Vortosiran is the most advanced FXI-targeting nucleic acid drug in global development. As of the date of this announcement, the product has completed a European Phase 2a clinical trial for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112507773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112507773","market":"other","top_or_hot":-1,"title":"RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism","media":"Stock News","content":"<p>RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE). This study is part of the company's broader program of planned Phase 2b trials targeting various thromboembolic cardiovascular indications. VTE remains a leading cause of morbidity and mortality in patients with cardiovascular disease, affecting approximately 10 million people globally each year. A significant proportion of these patients are inadequately treated or discontinue therapy due to the bleeding risks associated with current anticoagulant medications. Vortosiran is a small interfering RNA (siRNA) therapeutic designed for thromboembolic diseases. It works by precisely and durably inhibiting coagulation factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and suppressing FXI activity. This mechanism aims to provide robust protection against thromboembolism while significantly reducing the risk of bleeding. Compared to existing anticoagulant therapies, vortosiran has the potential to enhance clinical benefits for patients alongside a lower bleeding risk. Vortosiran is the most advanced FXI-targeting nucleic acid drug in global development. As of the date of this announcement, the product has completed a European Phase 2a clinical trial for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-11 17:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE). This study is part of the company's broader program of planned Phase 2b trials targeting various thromboembolic cardiovascular indications. VTE remains a leading cause of morbidity and mortality in patients with cardiovascular disease, affecting approximately 10 million people globally each year. A significant proportion of these patients are inadequately treated or discontinue therapy due to the bleeding risks associated with current anticoagulant medications. Vortosiran is a small interfering RNA (siRNA) therapeutic designed for thromboembolic diseases. It works by precisely and durably inhibiting coagulation factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and suppressing FXI activity. This mechanism aims to provide robust protection against thromboembolism while significantly reducing the risk of bleeding. Compared to existing anticoagulant therapies, vortosiran has the potential to enhance clinical benefits for patients alongside a lower bleeding risk. Vortosiran is the most advanced FXI-targeting nucleic acid drug in global development. As of the date of this announcement, the product has completed a European Phase 2a clinical trial for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1112507773","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112507773","pubTimestamp":1778492820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B核心产品Vortosiran提交静脉血栓栓塞症2b期临床试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE). This study is part of the company's broader program of planned Phase 2b trials targeting various thromboembolic cardiovascular indications. VTE remains a leading cause of morbidity and mortality in patients with cardiovascular disease, affecting approximately 10 million people globally each year. A significant proportion of these patients are inadequately treated or discontinue therapy due to the bleeding risks associated with current anticoagulant medications. Vortosiran is a small interfering RNA (siRNA) therapeutic designed for thromboembolic diseases. It works by precisely and durably inhibiting coagulation factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and suppressing FXI activity. This mechanism aims to provide robust protection against thromboembolism while significantly reducing the risk of bleeding. Compared to existing anticoagulant therapies, vortosiran has the potential to enhance clinical benefits for patients alongside a lower bleeding risk. Vortosiran is the most advanced FXI-targeting nucleic acid drug in global development. As of the date of this announcement, the product has completed a European Phase 2a clinical trial for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112507773","isCrawlerRequest":true}